| Theme | Treatment Strategy for Advanced Hepatocellular Carcinoma | |
|---|---|---|
| Title | Clinical Staging System for Hepatocellular carcinoma (HCC) | |
| Publish Date | 2015/07 | |
| Author | Satoshi Kitai | Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine |
| Author | Kazuomi Ueshima | Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine |
| Author | Masatoshi Kudo | Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine |
| [ Summary ] | The prognosis of hepatocellular carcinoma (HCC) patients, in particular, is defined not only by tumor status but also by liver function. Therefore, it is essential to establish and validate the best clinical staging method for HCC. A staging system for advanced HCC patients is important because it is used to evaluate patients for therapeutic indications, namely, for deciding who should receive positive treatment because of a good prognosis and who should receive palliative care because of a poor prognosis. The Japan integrated staging (JIS) score can be used to correctly identify the patient's subgroup from among early, intermediate, advanced, and end‒stage HCC patient subgroups ; this is of great benefit in clinical hepatology. The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used and best‒validated method for HCC classification. Most advanced HCC patients are classified into BCLC stage C, and sorafenib has become the treatment option of choice for these patients. |
|